Zydus Cadila receives final approval for Ambrisentan Tablets USP

Zydus Cadila has received the final approval from the USFDA to market Ambrisentan Tablets USP (US RLD Letairis Tablets), 5 mg and l0 mg. It is used to treat high blood pressure in the lungs (pulmonary arterial hypertension) and will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. The US sales of Ambrisentan Tablets USP stood at $ 943 million in 2018.

Powered by Capital Market - Live News